These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 21485624)

  • 1. Stakeholders say FDA must change REMS program.
    Reinke T
    Manag Care; 2011 Mar; 20(3):8-9. PubMed ID: 21485624
    [No Abstract]   [Full Text] [Related]  

  • 2. Food and Drug Administration's Safe Use Initiative collaborating to reduce preventable harm from medications.
    U S Food And Drug Administration
    J Pain Palliat Care Pharmacother; 2010 Mar; 24(1):76-93. PubMed ID: 20345207
    [No Abstract]   [Full Text] [Related]  

  • 3. Opioid risk management: understanding FDA mandated risk evaluation and mitigation strategies (REMS).
    Sloan PA
    J Opioid Manag; 2009; 5(3):131-3. PubMed ID: 19662921
    [No Abstract]   [Full Text] [Related]  

  • 4. Understanding risk evaluation and mitigation strategies in organ transplantation.
    Gabardi S
    Pharmacotherapy; 2011 Jul; 31(7):714-22. PubMed ID: 21923459
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Food and Drug Administration risk evaluation and mitigation strategy.
    Craig DS
    J Pain Palliat Care Pharmacother; 2010 Jun; 24(2):145-8. PubMed ID: 20504137
    [TBL] [Abstract][Full Text] [Related]  

  • 6. APhA 2011 REMS white paper: Summary of the REMS stakeholder meeting on improving program design and implementation.
    American Pharmacists Association ; Bough M
    J Am Pharm Assoc (2003); 2011; 51(3):340-58. PubMed ID: 21555285
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Extended-release/long-acting opioid REMS may fill the need for prescribers' appropriate use education.
    Nicholson SC; Evanyo K; Salinas GD; Roepke N; Burton BS; Susalka D
    J Opioid Manag; 2012; 8(4):212-6. PubMed ID: 22941848
    [TBL] [Abstract][Full Text] [Related]  

  • 8. FDA's risk evaluation and mitigation strategies (REMS): effective and efficient safety tools or process poltergeist?
    Wilson A; Milne CP
    Food Drug Law J; 2011; 66(4):569-85, ii. PubMed ID: 24505829
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Shared risk evaluation mitigation strategy for all immediate-release transmucosal fentanyl dosage forms.
    Food And Drug Administration, Public Health Service, U.S. Department Of Health And Human Services
    J Pain Palliat Care Pharmacother; 2012 Jun; 26(2):123-6. PubMed ID: 22764848
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Blueprint for prescriber continuing education program.
    Center For Drug Evaluation And Research Food And Drug Administration
    J Pain Palliat Care Pharmacother; 2012 Jun; 26(2):127-30. PubMed ID: 22764849
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Risk evaluation and mitigation strategies: impact on patients, health care providers, and health systems.
    Shane R
    Am J Health Syst Pharm; 2009 Dec; 66(24 Suppl 7):S6-S12. PubMed ID: 19966079
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Risk management of marketed drugs: FDA and the interface with the practice of medicine.
    Uhl K; Honig P
    Pharmacoepidemiol Drug Saf; 2001 May; 10(3):205-8. PubMed ID: 11501332
    [No Abstract]   [Full Text] [Related]  

  • 13. Class-wide REMS for extended-release and long-acting opioids: potential impact on pharmacies.
    Matthews ML
    J Am Pharm Assoc (2003); 2013; 53(1):e1-7. PubMed ID: 23636166
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Risk management of drug products and the U.S. Food and Drug Administration: evolution and context.
    Leiderman DB
    Drug Alcohol Depend; 2009 Dec; 105 Suppl 1():S9-S13. PubMed ID: 19307069
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The US Food and Drug Administration's Risk Evaluation and Mitigation Strategy (REMS) program in practice: does it really inform patients and limit risk?
    Cohen RA; Brown RS
    Am J Kidney Dis; 2012 May; 59(5):604-6. PubMed ID: 22361042
    [No Abstract]   [Full Text] [Related]  

  • 16. The Food and Drug Administration opioid Risk Evaluation and Mitigation Strategy.
    Lipman AG
    J Pain Palliat Care Pharmacother; 2009; 23(3):219-21. PubMed ID: 19670017
    [No Abstract]   [Full Text] [Related]  

  • 17. Meeting REMS head on.
    Walker S
    Health Manag Technol; 2011 Jul; 32(7):34. PubMed ID: 21863707
    [No Abstract]   [Full Text] [Related]  

  • 18. [Guidance of FDA risk evaluation and mitigation strategy and enlightenment to drug risk management of post-marketing Chinese medicine].
    Li Y; Xie Y
    Zhongguo Zhong Yao Za Zhi; 2011 Oct; 36(20):2825-7. PubMed ID: 22292376
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Anticipating REMS.
    Nat Rev Drug Discov; 2008 Dec; 7(12):963. PubMed ID: 19043440
    [No Abstract]   [Full Text] [Related]  

  • 20. The Food and Drug Administration Amendments Act of 2007: drug safety and health-system pharmacy implications.
    Meyer BM
    Am J Health Syst Pharm; 2009 Dec; 66(24 Suppl 7):S3-5. PubMed ID: 19966078
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.